353 related articles for article (PubMed ID: 26660078)
21. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
22. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
[TBL] [Abstract][Full Text] [Related]
23. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
Lee JW; Soung YH; Seo SH; Kim SY; Park CH; Wang YP; Park K; Nam SW; Park WS; Kim SH; Lee JY; Yoo NJ; Lee SH
Clin Cancer Res; 2006 Jan; 12(1):57-61. PubMed ID: 16397024
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications.
Imperial R; Toor OM; Hussain A; Subramanian J; Masood A
Semin Cancer Biol; 2019 Feb; 54():14-28. PubMed ID: 29175106
[TBL] [Abstract][Full Text] [Related]
25. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
26. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Ogino S; Meyerhardt JA; Cantor M; Brahmandam M; Clark JW; Namgyal C; Kawasaki T; Kinsella K; Michelini AL; Enzinger PC; Kulke MH; Ryan DP; Loda M; Fuchs CS
Clin Cancer Res; 2005 Sep; 11(18):6650-6. PubMed ID: 16166444
[TBL] [Abstract][Full Text] [Related]
27. Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease.
Kamionek M; Ahmadi Moghaddam P; Sakhdari A; Kovach AE; Welch M; Meng X; Dresser K; Tomaszewicz K; Cosar EF; Mark EJ; Fraire AE; Hutchinson L
Histopathology; 2016 Sep; 69(3):499-509. PubMed ID: 26915300
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
29. High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma.
Ishige T; Itoga S; Sato K; Kitamura K; Nishimura M; Sawai S; Matsushita K; Suzuki K; Ota S; Miyauchi H; Matsubara H; Nakatani Y; Nomura F
Clin Biochem; 2014 Dec; 47(18):340-3. PubMed ID: 25262986
[TBL] [Abstract][Full Text] [Related]
30. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.
Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421
[TBL] [Abstract][Full Text] [Related]
31. Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing.
Jauhri M; Bhatnagar A; Gupta S; Shokeen Y; Minhas S; Aggarwal S
Med Oncol; 2016 Oct; 33(10):106. PubMed ID: 27568332
[TBL] [Abstract][Full Text] [Related]
32. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
33. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
Georgieva M; Krasteva M; Angelova E; Ralchev K; Dimitrov V; Bozhimirov S; Georgieva E; Berger MR
Oncol Rep; 2008 Jul; 20(1):3-11. PubMed ID: 18575712
[TBL] [Abstract][Full Text] [Related]
35. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
36. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
[TBL] [Abstract][Full Text] [Related]
37. Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
Scheffler M; Holzem A; Kron A; Nogova L; Ihle MA; von Levetzow C; Fassunke J; Wömpner C; Bitter E; Koleczko S; Abdulla DSY; Michels S; Fischer R; Riedel R; Weber JP; Westphal T; Gerigk U; Kern J; Kaminsky B; Randerath W; Kambartel KO; Merkelbach-Bruse S; Büttner R; Wolf J
Lung Cancer; 2020 Jun; 144():40-48. PubMed ID: 32361034
[TBL] [Abstract][Full Text] [Related]
38. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
De Roock W; De Vriendt V; Normanno N; Ciardiello F; Tejpar S
Lancet Oncol; 2011 Jun; 12(6):594-603. PubMed ID: 21163703
[TBL] [Abstract][Full Text] [Related]
39. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
40. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
